Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVTN 204: HIV DNA Prime/rAd5 Boost Vaccine Trial
NCT00125970Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2005
- Primary completion
- Feb 2008
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of VRC-HIVDNA016-00-VP and VRC-HIVADV014-00-VP in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Local and systemic adverse reactions at 12 months, Unfractionated IFN-gamma ELISpot responses to HIV-1 peptide pools at Day 210 and 1 more. Started Sep 2005; status: completed.
02
Drugs
VRC-HIVDNA016-00-VPVRC-HIVADV014-00-VP
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00125970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125970.